Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for TG Therapeutics, Inc. (TGTX : NSDQ)
 
 • Company Description   
TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Number of Employees: 399

 
 • Price / Volume Information   
Yesterday's Closing Price: $38.87 Daily Weekly Monthly
20 Day Moving Average: 2,239,056 shares
Shares Outstanding: 153.08 (millions)
Market Capitalization: $5,950.38 (millions)
Beta: 1.68
52 Week High: $44.65
52 Week Low: $25.28
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.28% 0.14%
12 Week 25.79% 16.29%
Year To Date 30.39% 21.02%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3020 CARRINGTON MILL BLVD SUITE 475
-
MORRISVILLE,NC 27560
USA		 ph: 877-575-8489
fax: 212-554-4531		 ir@tgtxinc.com http://www.tgtherapeutics.com
 
 • General Corporate Information   
Officers
Michael S. Weiss - Chairman; Chief Executive Officer and President
Sean A. Power - Chief Financial Officer; Treasurer and Corporate S
Laurence N. Charney - Director
Yann Echelard - Director
Kenneth Hoberman - Director

Peer Information
TG Therapeutics, Inc. (CORR.)
TG Therapeutics, Inc. (RSPI)
TG Therapeutics, Inc. (CGXP)
TG Therapeutics, Inc. (BGEN)
TG Therapeutics, Inc. (GTBP)
TG Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 88322Q108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/03/26
Share - Related Items
Shares Outstanding: 153.08
Most Recent Split Date: 4.00 (0.02:1)
Beta: 1.68
Market Capitalization: $5,950.38 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.38 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.31 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 29.73
Trailing 12 Months: 13.36
PEG Ratio: -
Price Ratios
Price/Book: 10.20
Price/Cash Flow: 13.87
Price / Sales: 8.50
EPS Growth
vs. Year Ago Period: 466.67%
vs. Previous Quarter: 21.43%
Sales Growth
vs. Year Ago Period: 69.56%
vs. Previous Quarter: 6.41%
ROE
03/31/26 - 88.73
12/31/25 - 101.12
09/30/25 - 133.24
ROA
03/31/26 - 43.44
12/31/25 - 51.88
09/30/25 - 60.43
Current Ratio
03/31/26 - 5.81
12/31/25 - 4.10
09/30/25 - 3.82
Quick Ratio
03/31/26 - 5.12
12/31/25 - 3.29
09/30/25 - 2.89
Operating Margin
03/31/26 - 66.99
12/31/25 - 72.56
09/30/25 - 84.13
Net Margin
03/31/26 - 65.95
12/31/25 - 72.56
09/30/25 - 84.13
Pre-Tax Margin
03/31/26 - 17.46
12/31/25 - 17.42
09/30/25 - 16.50
Book Value
03/31/26 - 3.81
12/31/25 - 4.08
09/30/25 - 3.83
Inventory Turnover
03/31/26 - 0.85
12/31/25 - 0.69
09/30/25 - 0.55
Debt-to-Equity
03/31/26 - 1.28
12/31/25 - 0.38
09/30/25 - 0.40
Debt-to-Capital
03/31/26 - 56.10
12/31/25 - 27.49
09/30/25 - 28.78
 

Powered by Zacks Investment Research ©